

Bill introduced to increase access to Scalp Cooling Therapy

On Friday 1st April, in Washington D.C., the bill HB7322 was introduced to the House to require coverage for scalp cooling under group health plans and group and individual health insurance coverage, specified Federal health care programs, and the Federal Employees Health Benefits Program.

The legislation was introduced by House Appropriations Committee Chair Rosa DeLauro and would require all health insurers to provide coverage for scalp cooling treatments for the prevention of chemotherapy-induced alopecia for cancer patients.

Congresswoman DeLauro, herself a thirty-four-year cancer survivor commented,

"Hair loss is one of the most feared side effects for men and women diagnosed with cancer. Because most cancer patients' insurance does not cover scalp cooling therapy, they are forced to make a choice between incurring significant debt and therapy that can preserve the mental well-being and sense of normalcy during their fight with cancer."

The bill text is available here.

The next step for the bill is a vote by the full House Committee. It will then be considered by the Senate and the House of Representatives. If passed, the bill will require final approval by The President before it is signed into law.

Contacts

Richard Paxman, CEO Tel: +44 7968 020641 Email: richard@paxmanscalpcooling.com www.paxman.se

About Us

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 4,000 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN's scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US).

The PAXMAN share is listed on Nasdaq First North Growth Market. FNCA Sweden AB is the company's Certified Adviser and can be contacted via info@fnca.se and +46 (0)8 528 003 99.



Attachments

Bill introduced to increase access to Scalp Cooling Therapy